The Novel Proteasome Inhibitor 5-Amino-8-Hydroxyquinole (5AHQ) Overcomes Bortezomib Resistance in Malignant Hematological Cell Line Models Harboring Mutations in the PSMB5 Gene.

硼替佐米 蛋白酶体 蛋白酶体抑制剂 细胞培养 癌症研究 生物 药理学 多发性骨髓瘤 医学 化学 分子生物学 免疫学 生物化学 遗传学
作者
N. Franke,Johan van Meerloo,Linda M. Slot,Xiaoming Li,Tabitha E. Wood,Katarina Vojtekova,Sue Ellen Verbrugge,Gertjan J.L. Kaspers,Robert A. Batey,Aaron D. Schimmer,Gerrit Jansen,Jacqueline Cloos
出处
期刊:Blood [Elsevier BV]
卷期号:114 (22): 940-940 被引量:1
标识
DOI:10.1182/blood.v114.22.940.940
摘要

Abstract Abstract 940 The proteasome inhibitor Bortezomib (BTZ, Velcade®) specifically inhibits the catalytic beta 5 subunit of the proteasome, thereby interfering in the degradation of proteins involved in cell-cycling, NF-kB activation, apoptosis induction and micro-environmental interactions. The introduction of BTZ has shown promising results in the treatment of Multiple Myeloma (MM), Non-Hodgkin lymphoma and leukemia. Despite these encouraging results, clinical trials in MM also revealed that a significant proportion of patients acquired resistance to BTZ mono-therapy. Previously we reported the development of three different BTZ-resistant cell line models, including the AML THP-1 cell-line (Oerlemans & Franke et al, Blood 2008), the T-ALL CCRF-CEM-C7 cell-line and the MM RPMI-8226 cell line (Franke et al, ASH 2008) after chronic exposure to stepwise increasing concentrations of BTZ. The aim of our current study was to further elucidate the molecular basis of BTZ resistance in these cell lines and investigate whether the resistant phenotype could be overcome by the second generation proteasome inhibitor 5-amino-8-hydroxyquinole (5AHQ), acting as a non-competitive inhibitor of the non-catalytic alpha-7 subunit of the proteasome (Li et al. ASH 2008). When added to intact cells, cell extracts, or isolated rabbit reticulocyte proteasomes (gift of A Navon, Weizmann Institute of Science, Israel), 5AHQ inhibited the chymotrypsin-like enzymatic activity of the proteasome with IC50's of 6.9 ± 0.05 uM, 4.2 ± 0.6 uM, and 2.1 ± 0.18 μM, respectively. Cells were initially selected for growth at 7 nM BTZ to acquire low levels of BTZ resistance (2-3 fold higher IC50 concentrations) and subsequently challenged to higher concentrations of BTZ (up to 500 nM) to provoke higher resistance levels. Sequencing of the PSMB5 gene, encoding for the beta 5 proteasome subunit, revealed a series of mutations in individual BTZ-resistant subclones. An overview of the mutation site in the PSMB5 gene, the amino acid position at which substitutions take place at the beta 5 subunit protein level, and the functional implication of each mutation are depicted in the table below. Subsequently, we determined whether THP-1, CEM and 8226 cells with low and high levels of BTZ resistance would be sensitive towards the new proteasome inhibitor 5AHQ. Strikingly, all BTZ-resistant selectants retained full sensitivity towards 5AHQ (IC50: 4-7 μM, measured in a 4-day MTT cytotoxicity assay) as compared to parental cells. Together, these data indicate that in vitro selection of low and high levels of BTZ resistance in 3 hematological cell lines is accompanied by the introduction of multiple mutations of amino acids, all of which have key positions in BTZ binding within the active site of the proteasome beta 5 subunit. Notably, Ala49 mutations were independently observed in all 3 cell lines selected for BTZ concentrations > 100 nM. Knowledge of specific mutations in the PSMB5 gene that can confer BTZ resistance allows purposive screening for these types of mutations in clinical samples of BTZ refractory patients. In this respect, the notion that 5AHQ can bypass BTZ resistance related to single or multiple mutations in the PSMB5 gene, supports further preclinical development and clinical application of this drug. This study is supported by VUmc - Stichting Translational Research (STR) and The Netherlands Organization for Health Research and Development (ZonMw), The Leukemia and Lymphoma Society and the Ontario Institute for Cancer Research through funding from the Ministry of Research and Innovation, Province of Ontario. Disclosures: No relevant conflicts of interest to declare.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
1秒前
1秒前
2秒前
2秒前
2秒前
CHAO完成签到,获得积分10
2秒前
田様应助wdlc采纳,获得10
3秒前
angewbaby发布了新的文献求助10
3秒前
fcyyc发布了新的文献求助30
3秒前
goodsheep完成签到 ,获得积分10
3秒前
Ray完成签到,获得积分10
3秒前
4秒前
5秒前
5秒前
aaa发布了新的文献求助10
5秒前
Xixicccccccc完成签到 ,获得积分10
6秒前
Young_89发布了新的文献求助10
6秒前
SciGPT应助rui采纳,获得10
6秒前
大胆又夏发布了新的文献求助10
6秒前
7秒前
Hayley发布了新的文献求助10
7秒前
开心擎完成签到,获得积分20
7秒前
7秒前
fffxuy发布了新的文献求助10
8秒前
Ym完成签到,获得积分10
8秒前
跳跃寒风发布了新的文献求助10
8秒前
娟儿完成签到,获得积分10
8秒前
DijiaXu应助cxb采纳,获得10
8秒前
9秒前
9秒前
222222关注了科研通微信公众号
10秒前
yqwang发布了新的文献求助10
10秒前
10秒前
11秒前
我是老大应助runner采纳,获得10
12秒前
12秒前
邓紫棋完成签到,获得积分10
12秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975165
求助须知:如何正确求助?哪些是违规求助? 3519595
关于积分的说明 11198781
捐赠科研通 3255912
什么是DOI,文献DOI怎么找? 1798001
邀请新用户注册赠送积分活动 877343
科研通“疑难数据库(出版商)”最低求助积分说明 806298